




The relative strengths and weaknesses of Elicio Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Elicio Therapeutics Inc compared to the market average is the variable Selling, General and Administrative Expense, increasing the Economic Capital Ratio by 4.1% points. The greatest weakness of Elicio Therapeutics Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 47% points.

The company's Economic Capital Ratio, given in the ranking table, is 94%, being 121% points below the market average of 215%.

Input Variable	Value in 1000 USD
Assets, Current	20,693
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	11,523
Liabilities, Non-Current	5,105
Other Assets	7,002
Other Compr. Net Income	22
Other Expenses	0
Other Liabilities	22,862
Other Net Income	-6,912
Other Revenues	0
Property and Equipment	483
Research and Development	33,656
Selling, General and Administrative Expense	11,330

Output Variable	Value in 1000 USD
Assets	28,178
Liabilities	39,490
Expenses	44,986
Revenues	0
Stockholders Equity	-11,312
Net Income	-51,898
Comprehensive Net Income	-51,887
BaseVar	59,794
ECR before Limited Liability	-226%
Economic Capital Ratio	94%